Synchronous hepatocellular carcinoma and Castleman's disease: The role of the interleukin-6-signaling pathway

Hepatology ◽  
2012 ◽  
Vol 56 (1) ◽  
pp. 392-393 ◽  
Author(s):  
Yun Shin Chun ◽  
Julien Calderaro ◽  
Jessica Zucman-Rossi
Nephron ◽  
1998 ◽  
Vol 78 (3) ◽  
pp. 323-327 ◽  
Author(s):  
Sing-Leung Lui ◽  
Kwok-Wah Chan ◽  
Fu-Keung Li ◽  
Ignatius K.P. Cheng ◽  
Tak-Mao Chan

2019 ◽  
Vol 10 (6) ◽  
pp. 1570-1579 ◽  
Author(s):  
Qinfeng Huang ◽  
Junhong Li ◽  
Jinghui Zheng ◽  
Ailing Wei

Blood ◽  
1989 ◽  
Vol 74 (4) ◽  
pp. 1360-1367 ◽  
Author(s):  
K Yoshizaki ◽  
T Matsuda ◽  
N Nishimoto ◽  
T Kuritani ◽  
L Taeho ◽  
...  

Abstract Castleman's disease is a syndrome consisting of giant lymph node hyperplasia with plasma cell infiltration, fever, anemia, hypergammaglobulinemia, and an increase in the plasma level of acute phase proteins. It has been reported that clinical abnormalities disappear after the resection of the affected lymph nodes, suggesting that products of lymph nodes may cause such clinical abnormalities. Interleukin-6 (IL-6) is a cytokine inducing B-cell differentiation to immunoglobulin-producing cells and regulating biosynthesis of acute phase proteins. This report demonstrates that the germinal centers of hyperplastic lymph nodes of patients with Castleman's disease produce large quantities of IL-6 without any significant production of other cytokines. In a patient with a solitary hyperplastic lymph node, clinical improvement and decrease in serum IL-6 were observed following surgical removal of the involved lymph node. There was a correlation between serum IL-6 level, lymph node hyperplasia, hypergammaglobulinemia, increased level of acute phase proteins, and clinical abnormalities. The findings in this report indicate that the generation of IL-6 by B cells in germinal centers of hyperplastic lymph nodes of Castleman's disease may be the key element responsible for the variety of clinical symptoms in this disease.


2014 ◽  
Vol 18 (3) ◽  
pp. 154-155
Author(s):  
Yue-Sun Cheung ◽  
Anthony Wing-Hung Chan ◽  
Kit-Fai Lee ◽  
John Wong ◽  
Charing Ching-Ning Chong ◽  
...  

Cytokine ◽  
2002 ◽  
Vol 20 (6) ◽  
pp. 304-311 ◽  
Author(s):  
Asao Katsume ◽  
Hiroyuki Saito ◽  
Yoshiki Yamada ◽  
Keigo Yorozu ◽  
Otoya Ueda ◽  
...  

2016 ◽  
Vol 136 (1) ◽  
pp. 16-22
Author(s):  
Musa Fares Alzahrani ◽  
Mansoor Radwi ◽  
Heather A. Leitch

Castleman's disease (CD) is a rare lymphoproliferative disorder that is most commonly present in multicentric (MCD) form in association with HIV infection. Interleukin-6 (IL-6) and human herpesvirus-8 (HHV-8) play major roles in MCD pathogenesis. Important treatment options have recently become available, particularly with the introduction of IL-6 and IL-6 receptor inhibitors for the treatment of HIV-negative patients with MCD. Though advances in therapy may improve outcomes in some patients, the prognosis remains guarded, and a stratified approach to the management of MCD is needed.


Sign in / Sign up

Export Citation Format

Share Document